Taysha Gene Therapies, Inc. (NasdaqGS: TSHA)
Health Care · Biotechnology · US
$5.98
-3.55% today · +109.5% 1Y
Taysha Gene Therapies, Inc. (NasdaqGS: TSHA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.02B and employs 99 people.
Over the last twelve months the share price has gained 109.5%, trading between 2.71 and 7.30.
Tweenvest scores Taysha Gene Therapies, Inc. across four factors: quality 28/100, value 69/100. Its strongest factor is value.
TSHA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.02B
- Revenue (TTM)
- $5.49M
- P/E
- —
- EPS
- -0.41
- Dividend yield
- —
- Beta (5Y)
- 1.19
- 52-week high
- $7.30
- 52-week low
- $2.71
- Avg volume (3M)
- —
- Shares outstanding
- 325.83M
- Employees
- 99
- Next earnings
- —
About Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.
- ISIN
- US8776191061
- Founded
- 2019
- Listed since
- Sep 24, 2020
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $262.42 | -1.27% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $440.10 | -0.48% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.70 | -0.05% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $549.79 | -0.55% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $822.15 | -1.37% |
| argenx SEENXTBR: ARGX | $64.17B | €889.60 | +1.18% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $149.44 | -5.91% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.